Actively Recruiting
A Study of SHR-2906 Injection in Healthy Subjects With a Single Dose and in Obese Patients With Multiple Doses
Led by Beijing Suncadia Pharmaceuticals Co., Ltd · Updated on 2026-05-14
124
Participants Needed
1
Research Sites
47 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is a randomized, double-blind, placebo-controlled, dose-escalation phase I clinical trial. This study consists of two parts: the single-dose escalation study (SAD) in healthy subjects and the multiple-dose escalation study (MAD) in obese patients.
CONDITIONS
Official Title
A Study of SHR-2906 Injection in Healthy Subjects With a Single Dose and in Obese Patients With Multiple Doses
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Voluntarily sign informed consent and agree to follow the study procedures
- Male or female aged 18 to 55 years
- Generally healthy based on medical history, vital signs, physical exam, lab tests, and ECG
- BMI between 19.0 and 23.9 kg/m2 for Part I or between 28.0 and 35.0 kg/m2 for Part II
You will not qualify if you...
- ECG showing QTcF >450 ms in males or >470 ms in females or other clinically significant abnormalities
- Endocrine diseases or history affecting body weight (e.g., Cushing's syndrome, diabetes, thyroid disorders)
- History or family history of medullary thyroid carcinoma, multiple endocrine adenomatosis type 2, pancreatitis, or symptomatic gallbladder disease
- Significant clinical conditions in the past 12 months affecting gastrointestinal, kidney, liver, nervous, blood, endocrine, tumor, lung, immune, mental, cardiovascular, or cerebrovascular systems
- Use of prescription, OTC drugs, supplements, vitamins (except conventional), or Chinese herbal medicines within 2 weeks prior to screening
- Prior gastrointestinal surgery causing malabsorption or recent use of drugs affecting gastrointestinal peristalsis or weight-reducing drugs within 3 months
- History of drug abuse in past 5 years or drug use in past 3 months; positive urine drug screen
- Blood donation ≥200 mL within 1 month or ≥400 mL blood loss/donation within 3 months prior to screening
- Inability to tolerate blood draws or fainting at sight of needles or blood
- Special dietary requirements making uniform diet compliance impossible
- Any other factors deemed unsuitable by researchers for trial participation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Hangzhou First People's Hospital
Hangzhou, Zhejiang, China, 310006
Actively Recruiting
Research Team
Z
Zi Ye
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here